{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-25-000003","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.987358+00:00","generated_at":"2026-05-26T08:44:31.690074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prothena reports FY2024 net loss $122.3M; cash $472.2M; AFFIRM-AL topline expected Q2 2025","bullets":["Net loss per share Q4 $1.08, FY2024 $2.27; total revenue FY2024 $135.2M (up from $91.4M prior year).","Cash $472.2M at Dec 31, 2024, no debt; 2025 guidance: net cash burn $168-175M, year-end cash ≈$301M.","Confirmatory Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.","PRX012 Phase 1 ASCENT readouts starting mid-2025; BMS started Phase 2 for BMS-986446; $80M received for PRX019 license.","Roche's prasinezumab Phase 2b PADOVA missed primary endpoint but showed trends; Roche to discuss next steps with health authorities."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-25-000003","json":"https://secwatch.observer/filing/0001559053-25-000003.json","markdown":"https://secwatch.observer/filing/0001559053-25-000003.md","text":"https://secwatch.observer/filing/0001559053-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905325000003/0001559053-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905325000003/prta-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:44:31.690074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}